412 related articles for article (PubMed ID: 35074571)
1. An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).
Elahi R; Karami P; Heidary AH; Esmaeilzadeh A
Int Immunopharmacol; 2022 Apr; 105():108536. PubMed ID: 35074571
[TBL] [Abstract][Full Text] [Related]
2. The role of IL-6 and IL-6 blockade in COVID-19.
Potere N; Batticciotto A; Vecchié A; Porreca E; Cappelli A; Abbate A; Dentali F; Bonaventura A
Expert Rev Clin Immunol; 2021 Jun; 17(6):601-618. PubMed ID: 33874829
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
4. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease.
Zhou Z; Price CC
Expert Opin Investig Drugs; 2020 Dec; 29(12):1407-1412. PubMed ID: 33094669
[TBL] [Abstract][Full Text] [Related]
5. Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine.
Dzobo K; Chiririwa H; Dandara C; Dzobo W
OMICS; 2021 Jan; 25(1):13-22. PubMed ID: 32857671
[TBL] [Abstract][Full Text] [Related]
6. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation.
Della-Torre E; Lanzillotta M; Campochiaro C; Cavalli G; De Luca G; Tomelleri A; Boffini N; De Lorenzo R; Ruggeri A; Rovere-Querini P; Castagna A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; Dagna L
Front Immunol; 2021; 12():675678. PubMed ID: 33995419
[TBL] [Abstract][Full Text] [Related]
7. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
8. Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations.
Marino A; Munafò A; Augello E; Bellanca CM; Bonomo C; Ceccarelli M; Musso N; Cantarella G; Cacopardo B; Bernardini R
Infect Dis Rep; 2022 May; 14(3):360-371. PubMed ID: 35645219
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibition as a new treatment strategy for patients with COVID-19.
Huang J; Zhou C; Deng J; Zhou J
Biochem Pharmacol; 2022 Aug; 202():115162. PubMed ID: 35787993
[TBL] [Abstract][Full Text] [Related]
10. Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19.
Talukdar J; Bhadra B; Dattaroy T; Nagle V; Dasgupta S
Biomed Pharmacother; 2020 Dec; 132():110886. PubMed ID: 33113418
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.
Bahari Z; Jangravi Z; Ghoshooni H; Afarinesh MR; Meftahi GH
Inflamm Res; 2021 Apr; 70(4):389-405. PubMed ID: 33608746
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications.
Majidpoor J; Mortezaee K
Biomed Pharmacother; 2022 Jan; 145():112419. PubMed ID: 34781146
[TBL] [Abstract][Full Text] [Related]
13. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
[TBL] [Abstract][Full Text] [Related]
15. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
16. Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade.
Bahmani M; Chegini R; Ghanbari E; Sheykhsaran E; Shiri Aghbash P; Leylabadlo HE; Moradian E; Kazemzadeh Houjaghan AM; Bannazadeh Baghi H
World J Virol; 2022 May; 11(3):113-128. PubMed ID: 35665236
[TBL] [Abstract][Full Text] [Related]
17. Rethinking interleukin-6 blockade for treatment of COVID-19.
Scherger S; Henao-Martínez A; Franco-Paredes C; Shapiro L
Med Hypotheses; 2020 Nov; 144():110053. PubMed ID: 32758889
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
19. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
[TBL] [Abstract][Full Text] [Related]
20. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.
Du P; Geng J; Wang F; Chen X; Huang Z; Wang Y
Int J Med Sci; 2021; 18(6):1356-1362. PubMed ID: 33628091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
